How NYU researchers found a way to predict Zika infection in the public health emergency
New York University researchers have found a method for predicting Zika infection based on a novel biomarker, one of the first to be published in a peer-reviewed journal.
The biomarker can be used in the prediction of Zika infections, but it has a few key limitations.
A paper on the study, which was recently published in the journal Science Advances, describes how it was possible to identify the biomarker’s ability to predict viral load in a clinical trial involving about 20,000 people who had recently been exposed to the Zika virus.
The team also discovered a way for the biomarkers to predict whether or not the person who had Zika infection would have detectable Zika antibodies in the blood.
Researchers from the university’s New York City School of Medicine and the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases (NIAID) worked together to develop the biomarking technology.
The researchers hope that the discovery of the biomarkered Zika biomarker will lead to improved diagnostic and therapeutic methods that can be more easily administered.
They also hope to improve their biomarker and test methods, as well as make it easier for public health agencies to use the biomarkering to assess the potential health impact of a Zika virus outbreak.
The discovery was made in collaboration with researchers from the University of California, San Diego, and the New York State Department of Health and Mental Hygiene.
In a study published earlier this month in the Journal of the American Medical Association, the researchers tested the ability of a novel Zika biomarkers assay to predict the viral load of the virus in blood samples of a group of people who previously tested positive for Zika infection.
They found that a biomarker that can detect the Zika antibodies of Zika infection can predict the likelihood that the person with Zika infection will have detectable antibodies.
The research, led by Michael Ziebart, PhD, professor of public health and epidemiology at NYU Langone Medical Center and associate director of the NIAID Zika Virus Center, used a new assay to detect the antibodies of a small group of Zika virus infections in blood from people who were previously infected with the virus.
By combining the biomarkership and a viral load assay, Zieart and his team could determine whether a person with detectable Zika virus antibodies had a chance of having Zika antibodies detectable in the bloodstream of a person who tested positive.
The new method, they reported, was able to identify a small percentage of people whose viral load showed signs of infection that were consistent with Zika virus infection.
This is important because, if these people are found to have Zika antibodies, they could potentially infect people who have been infected with Zika.
Zika virus is transmitted by mosquito bites.
Because Zika is a mosquito-borne disease, it is a relatively easy to diagnose disease to a health care provider and it is not very difficult to treat.
Ziebarbs team used the biomarketry assay to analyze a group who had been previously infected and were tested for Zika antibodies.
They tested all of the people who tested negative, but then tested a subset of them.
They then analyzed the antibodies from these people and identified those that were more likely to have detectable virus in their blood, as measured by the Zika biomarkering assay.
This analysis allowed the team to identify and measure the antibody levels in blood that are most predictive of whether or how the person would have Zika infection if he or she had Zika antibodies detected in their bloodstream.
Zies research team then applied the Zika detection method to the blood of another group of participants and, as expected, found that the people with Zika antibodies were less likely to be tested positive than the people without Zika antibodies who tested at the same time.
This finding is important, Zies team wrote in the paper.
Because of the relatively high percentage of participants with Zika antibody levels that were detectable in blood, these participants were likely to spread Zika virus to others.
This increased risk for transmission of Zika was important because the Zika vaccine currently being tested in the United States does not target the antibodies.
It has been shown to reduce the risk of Zika transmission by about 95 percent, but Zies lab had not yet identified the biomarkery biomarker or tested its methods in clinical trials.
This study demonstrates that the Zika-specific biomarker is capable of predicting viral load from blood in the clinical setting.
This new technology allows the development of new diagnostic and treatment strategies to be used for patients who have Zika infections.
The scientists said that this study will be useful to other public health organizations, health professionals, and others in the field.
This work is being supported by grants from the National Institutes of Health (NIH), the National Center for Research Resources, the National Science Foundation, the American Institutes for Health Research (NIHR), and the Robert Wood Johnson Foundation.
The National Institutes for Allergy & Infectious Disease, NIAIDs, and NYS DHHS are all involved in the study.
For more information, visit: http://www